Small Molecule Targeted Cancer Therapy Market – An Overview of Growth Factors

Small molecule targeted cancer therapies are drugs designed to block the growth of cancerous cells. Conventional cytotoxic medications and chemotherapies usually destroys rapidly dividing cancer cells by inhibiting cell division process. However, small molecule targeted therapies destroys cancerous cells with fewer side effects and high precision. Small molecule targeted cancer therapies can be used for the treatment of various cancers such as prostate cancer, multiple myeloma, breast cancer, lymphoma, melanoma and other cancers.

Read Full Report: http://www.transparencymarketresearch.com/small-molecule-targeted-cancer-therapy-market.html

Targeted cancer drugs are broadly classified as follows:

  • Small Molecules
  • Monoclonal Antibodies
  • Small Molecule Drug conjugates

Small molecules can further be classified as follows:

  • Small molecule proteasome inhibitor (e.g. Bortezomib)
  • Small molecule cyclin-dependent kinase inhibitor (e.g. Seliciclib)
  • Small molecule tyrosine kinase inhibitor (e.g. Imatinib)

Geographically, North America is the leading market due to the rise incancer cases. According to the International Agency for Research on Cancer (IARC), around 13 million new cancer cases has been diagnosed worldwide. Moreover, according to the World Cancer Report, incidence rate of cancer could further rise by 50% to 15 million new cancer cases by 2020. Furthermore, the European and Asian-Pacific regions are expected to witness increased market traction due to commercialization of target oriented economic drugs.

Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2107

The major factors driving this market are rise in incidence rate of cancer, minimal adverse effects, targeted approach and high adoption rate. Additionally, more number of blockbuster drugs such as Novartis’s Glivec are losing their patents, leaving significant opportunities for manufacturers of targeted cancer drugs. However, high developmental costs, stringent regulatory policies andlow awareness are some of the restraints that could impede the growth of the market.

Some of the market players in this industry segment are Abbott Laboratories, Bayer HealthCare AG, Boehringer Ingelheim GmbH, CytokineticsInc., GlaxoSmithKline plc, Hospira Inc. , OncoGenex Pharmaceuticals Inc., and others.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net